Related Experiment Video
Updated: Jul 27, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Abstract:
The final overall survival (OS) results for the ADAURA trial show that osimertinib reduces the risk of death by 51% in patients with EGFR-mutated non-small cell lung cancer. For stage II or IIIA disease, the 5-year OS was 85% in patients who received osimertinib and 73% in the control group. The findings were nearly identical when patients with stage IB tumors were included in the analysis.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Treatment Resistant Cancers
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...